KYORIN and Acadia Pharmaceuticals Enter into Distribution Agreement for DAYBUE® STIX (Trofinetide) for Rett Syndrome in Japan
November 16, 2026
KYORIN Pharmaceutical Co., Ltd. announced that it has entered into an exclusive distribution agreement on November 13, 2026, with Acadia Pharmaceuticals Inc. (San Diego U.S., CEO: Catherine Owen Adams), for DAYBUE® STIX (generic name: trofinetide), a treatment for Rett syndrome for which Acadia holds the rights.
Under this agreement, KYORIN has obtained exclusive rights to commercialize trofinetide for Rett syndrome in Japan. KYORIN will make an upfront payment of USD 30 million to Acadia, along with milestone payments of up to USD 45 million upon NHI price listing and the achievement of certain net sales targets, and other payments.
Trofinetide is a synthetic analogue of GPE (glycine-proline-glutamate), an endogenous tripeptide derived from the N-terminal domain of IGF-1 (insulin-like growth factor 1), which plays an important role in the normal development and function of the nervous system. In the United States, it has been marketed since 2023 as DAYBUE and DAYBUE STIX for the treatment of Rett syndrome in adults and pediatric patients two years of age and older. In Japan, trofinetide has been granted Orphan Drug Designation, and Acadia has completed a Phase 3 clinical trial demonstrating results consistent with the U.S. LAVENDER study.
Based on the results of this Phase 3 clinical trial, KYORIN will submit an application for manufacturing and marketing approval in Japan on behalf of Acadia. Following NHI drug price listing, KYORIN will receive product supplies from Acadia and exclusively commercialize trofinetide in Japan.
KYORIN aims to create high-value new drugs that meet medical needs and has prioritized the "Expansion of development pipeline through in-licensing" under its medium-term vision, "Vision 110-Stage2-". Through this agreement, we are committed to actively advancing development to deliver new treatment options to patients as soon as possible, thereby contributing to people's health.
The impact on the consolidated financial forecasts for the fiscal year ending March 31, 2027 is expected to be negligible. The upfront payment to Acadia under this agreement has already been factored into the full-year consolidated forecasts and is expected to be recorded as SG&A expenses (R&D expenses) in the third quarter of the current fiscal year.
There are no capital, personnel, or business relationships between Acadia and KYORIN, and neither party is considered a related party to the other.
Please see the PDF file below for details.
